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Introduction
Ketoconazole, an imidazole derivative used to treat systemic fungal infections, has been associated with hepatic injury. Several reports have described icteric reactions with ketoconazole,'9 some fatal. ',2 14 Hepatic injury without overt jaundice has also been described. 2 In addition, asymptomatic transient increased activity of serum transaminase has been reported in some patients 28918 Ketoconazole was introduced in the United Kingdom in 1981 . By November 1984 the Committee on Safety ofMedicines had received 82 reports of possible hepatotoxicity in patients taking oral ketoconazole, including five deaths.' As a result the use of the drug is now restricted to patients who have conditions that do not respond to topical treatment. This study analyses the cases reported in the United Kingdom and examines the nature of the injury.
Patients and methods
By November 1984 follow up information had been obtained on 75 of the 82 cases reported on yellow cards (adverse reaction reporting forms) to the Committee on Safety of Medicines. The available data included sex and age, but in the interests of confidentiality no other details on patient identification were supplied. Also included were data on the condition being treated, relevant history, concomitant drug treatment, alcohol history, dose and duration of ketoconazole treatment, and the interval between the start of drug treatment and the onset of symptoms. The results of liver function tests, serology for hepatitis A (hepatitis A virus IgM) and hepatitis B (hepatitis B surface antigen), and large bile duct visualisation (cholecystogram, ultrasound scans, or technetium-99 N-N'-(2,6-dimethylphenyl) carbamoylmethyl iminodiacetic acid (HIDA) scans) and the final clinical outcome were also given. The results of histological examination of the liver in five cases, including three deaths, were reviewed by one of us (PJS).
Definition of hepatic injury-The pattern of hepatic injury was defined on the basis of the peak values for the serum liver function tests (table I) . Where the results of liver function tests were not available the report was defined as unclassified. Validation criteria-The classifiable reports were divided into three categories of association: probable (group 1), possible (group 2), or unlikely, depending on the extent to which common causes of hepatic injury had been excluded. Table II shows the criteria on which the classification was based. The association was considered to be unlikely when there was overwhelming evidence to support an alternative diagnosis. The concomitant intake of drugs or alcohol was not included in the criteria as this is often difficult to verify. Table III shows the 16 cases in group 1 that were considered to be related to drug treatment. Eleven patients (69%) were women. The mean (SD) age of the group was 57-9 (13-1) years (range 36 to 79). The mean duration of treatment before the onset of symptoms of hepatitis was 61-2 (five) days showed necrosis predominantly in acinar zone 3 as well as bridging between portal tracts and terminal hepatic venules. There was a moderate, mixed inflammatory infiltrate in the sections with necrosis as well as in portal tracts, which contained many proliferated bile ducts. Cholestasis in the form of bile thrombi within canaliculi was seen in surviving parenchymal areas. The changes were not like those seen after a reaction such as that caused by paracetamol toxicity and were consistent with either drug idiosyncrasy or viral hepatitis. The second patient was a 70 year old man with mitral valve disease who had been treated for a fungal toe infection with 200 mg ketoconazole daily. Many ofthe histological changes seen in specimens of liver taken at necropsy were considered to be secondary to the underlying cardiac disease. Such changes included extensive fibrosis in perivenular regions and some old fibrous narrowing of veins. Bridging fibrosis was also present, and there was moderate inflammatory infiltration. Frank necrosis was not evident, and the minor degree of liver cell degeneration seen was consistent with agonal hypoperfusion injury. There was severe canalicular cholestasis (fig 2) , the cause of which could not be established with certainty but which was compatible with injury by drugs.
Results

PROBABLE ASSOCIATION
The third death was that of a 57 year old woman who had been treated for 28 days with 400 mg ketoconazole for chronic monilial vulvovaginitis. About eight weeks after she stopped taking ketoconazole she developed malaise and later became jaundiced. The results of liver function tests suggested a primary hepatocellular pattern ofliver damage. Five weeks after the onset of jaundice she died in hepatic failure. A small needle biopsy specimen showed panacinar necrosis with proliferation of bile ductules and infiltration by lymphoid cells and segmented leucocytes. The surviving parenchyma showed cholestasis and evidence of regeneration in the form of thickened liver cell plates. The appearance was like that caused by severe hepatitis starting some weeks or months previously. In all three patients who died bile was present in ductules of a type described in sepsis. 9 One of the two liver biopsy specimens taken from patients who did not die showed minimal infiltration of the portal tracts, evidence of recent loss of liver cells, in the form of ceroid laden macrophages and reticulum condensation, and cholestasis. The second specimen showed canalicular cholestasis in perivenular regions that had little inflammation but mild hepatocellular swelling and increased multinucleation. The cholestasis that showed up on histological examination was probably induced by drugs but the possibility that it, like the ductular cholestasis, was related to sepsis could not be completely excluded. 
Discussion
The findings reported here are similar to those described previously.6420 In the 33 cases described by Lewis et al 55% of the patterns obtained from liver function tests showed primarily hepatocellular damage and 25% showed mixed damage. 14 In contrast with our histological findings, however, cholestasis was not a major histological feature in any of their three patients for whom the results of histological examination were available.
The age and sex distribution ofpatients developing liver reactions to ketoconazole may merely reflect the profile of patients treated with the drug. Other workers, however, have described a considerable contrast between the age distribution of patients who develop hepatitis and the age distribution of patients in whom the drug is used.620 In common with many hepatic drug reactions middle aged women seem to be particularly susceptible.
Most patients recovered when they stopped taking the drug, the results of their liver function tests returning to normal within an average of 3 1 months (range seven days to six months). Ofthe three fatal cases in group 1, two patients had continued to receive treatment after symptoms of hepatitis and jaundice had developed, a pattern described in previous reports.64 In the third the results of histological examination of the liver suggested that subclinical hepatitis with severe necrosis might have occurred initially during treatment with the drug. The patient remained asymptomatic for two months but later developed hepatic decompensation. To our knowledge this is the first such case described, and it underlines the need for regular biochemical monitoring during prolonged treatment.
The mechanism of liver damage induced by ketoconazole is unclear. The reaction seems to be idiosyncratic. The low incidence of fever, rash, and eosinophilia and the absence of eosinophil rich infiltrations or granulomas in liver tissue are uncharacteristic of an immune mediated reaction, as is the variable duration of drug administration before the onset of liver injury (four to 270 days). This variability has been reported previously.6 4 No rechallenge with the drug was well documented for our patients. Other workers, however, have found that rechallenge is not followed by prompt recurrence as might be expected in an allergic phenomenon.' Though a second course of treatment in two of the patients in group 2 was followed by a prompt recurrence of the reaction, the poor record of liver dysfunction makes interpretation difficult. The possibility that immune hypersensitivity mechanisms may be partly responsible for liver damage cannot therefore be totally excluded.
Paracetamol is one of many metabolites of ketoconazole in the dog.2 Paracetamol overdose leads to liver damage in man. The amount of paracetamol generated by the normal therapeutic dosage of ketoconazole, however, is unlikely to be significant. Furthermore, the results of histological examination were not characteristic of paracetamol toxicity.
Recent data have suggested that ketoconazole might interfere with the synthesis of deoxyribonucleic acid (DNA).22 This might result in cumulative damage over a variable period, culminating in overt dysfunction of liver cells. The idiosyncratic nature of the damage might be due to genetically determined differences in DNA repair mechanisms or to individual differences in drug metabolism.
Serious hepatic toxicity caused by ketoconazole treatment is rare and has been estimated to be about 1/15 000 exposed patients.'4 Our results confirm those of Lewis et al, which showed that hepatitis caused by ketoconazole is rare during the first week of treatment. ) 4 The risks are therefore minimal with treatment of short duration (<10 days) but seem to be greater with prolonged treatment. Hepatitis associated with ketoconazole is usually reversible when treatment is stopped. Fatal cases have occurred when treatment has been continued after symptoms of hepatitis have developed. Data from one of the cases described in this report suggest that severe hepatitis may occur subclinically during prolonged treatment with ketoconazole. It is currently not possible to predict which individuals are susceptible to liver damage, so it would seem prudent to instruct patients to stop following the treatment as soon as any symptoms suggestive of hepatitis (malaise, dark urine, pruritus) occur and before overt jaundice develops. Liver function tests should be performed before treatment to exclude hepatitis. Biochemical tests should be performed after the first 10 days of treatment and then twice a month during treatment with ketoconazole.
Transient asymptomatic increases in serum transaminase activity also occur during treatment with ketoconazole6 as during treatment with several other drugs. These increases are generally considered to be harmless but should alert the doctor to perform a further test within one week, as they could signal early hepatotoxicity. If the 
